{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"tirzepatide-surmount-1-2539-adults-72-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/es\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"Tirzepatide SURMOUNT-1: 2,539 Adultos durante las semanas 72"},"content":{"rendered":"<h2>Por qu\u00e9 SURMOUNT-1 es un estudio ancla \u00fatil<\/h2>\n<p>SURMOUNT-1 es un gran ensayo en fase aleatorizado 3 con un grupo de placebo y criterios de valoraci\u00f3n coprimarios preespecificados. Por lo tanto, respalda una discusi\u00f3n sobre evidencia cl\u00ednica m\u00e1s s\u00f3lida que las afirmaciones mecanicistas o las observaciones no controladas. El art\u00edculo tambi\u00e9n informa el conjunto completo de grupos de dosis aleatorias en lugar de un n\u00famero elegido selectivamente.<\/p>\n<h2>Poblaci\u00f3n y puntos finales<\/h2>\n<p>El ensayo inscribi\u00f3 a adultos con BMI de al menos 30, o al menos 27 con una complicaci\u00f3n relacionada con el peso, y excluy\u00f3 la diabetes. Los participantes fueron asignados al azar por igual a tres grupos de tirzepatida o placebo. La estimaci\u00f3n del r\u00e9gimen de tratamiento evalu\u00f3 los resultados independientemente de la interrupci\u00f3n del tratamiento en la poblaci\u00f3n por intenci\u00f3n de tratar.<\/p>\n<h2>Resultados en contexto<\/h2>\n<p>Los tres grupos de tirzepatida difirieron del placebo en los criterios de valoraci\u00f3n de peso informados. El art\u00edculo tambi\u00e9n informa los eventos adversos gastrointestinales como los m\u00e1s comunes, generalmente durante el aumento, y proporciona porcentajes de interrupci\u00f3n para cada grupo aleatorizado. Mantener visibles esos denominadores y datos de eventos adversos evita un resumen \u00fanicamente de eficacia.<\/p>\n<div class=\"pfm-case-callout\"><strong>L\u00edmite de comparaci\u00f3n:<\/strong> SURMOUNT-1 no fue un ensayo de retatrutida y no puede proporcionar una clasificaci\u00f3n directa de Retatrutide versus Tirzepatide. Los porcentajes entre ensayos provienen de diferentes protocolos y etapas de desarrollo.<\/div>\n<h2>Distinci\u00f3n de medicamento terminado<\/h2>\n<p>Los resultados cl\u00ednicos de un medicamento terminado revisado por un regulador no se pueden transferir a un material que comparte el mismo nombre pero que carece de la misma formulaci\u00f3n, sistema de administraci\u00f3n, especificaciones de liberaci\u00f3n y controles de calidad. Esta distinci\u00f3n es parte del expediente de pruebas, no una nota a pie de p\u00e1gina.<\/p>","protected":false},"excerpt":{"rendered":"<p>Una lectura estructurada del ensayo SURMOUNT-1 Fase 3, que preserva el dise\u00f1o aleatorio, los resultados de cuatro grupos, los datos de discontinuaci\u00f3n y la distinci\u00f3n entre un medicamento terminado aprobado y un material de uso en investigaci\u00f3n.<\/p>","protected":false},"author":0,"featured_media":851,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatide SURMOUNT-1 Trial: 2,539 Adults<\/title>\n<meta name=\"description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\" \/>\n<meta property=\"og:description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1 Trial: 2,539 Adults\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ensayo Tirzepatide SURMOUNT-1: 2,539 Adultos","description":"Una lectura estructurada del ensayo SURMOUNT-1 Fase 3, que preserva el dise\u00f1o aleatorio, los resultados de cuatro grupos, los datos de discontinuaci\u00f3n y la distinci\u00f3n entre un medicamento terminado aprobado y un material de uso en investigaci\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_locale":"es_ES","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks","og_description":"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.","og_url":"https:\/\/nhdbio.com\/es\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"Ensayo Tirzepatide SURMOUNT-1: 2,539 Adultos","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Una lectura estructurada del ensayo SURMOUNT-1 Fase 3, que preserva el dise\u00f1o aleatorio, los resultados de cuatro grupos, los datos de discontinuaci\u00f3n y la distinci\u00f3n entre un medicamento terminado aprobado y un material de uso en investigaci\u00f3n.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/723\/revisions\/728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/851"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}